Another opportunity to share your experience and preferences about treatments – make a PBAC submission for Vyvgart® in subcutaneous injection form
Another opportunity to share your experience and preferences about treatments – make a PBAC submission for Vyvgart® in subcutaneous injection form
The Pharmaceutical Benefits Advisory Committee (PBAC) will assess the subcutaneous injection form of Vyvgart® (efgartigimod alfa) for acetylcholine receptor autoantibody positive (AChR+) gMG patients at its meeting in November 2025.
Efgartigimod alfa is a neonatal Fc receptor (FcRn) inhibitor treatment that represents a new pathway in treating MG as it targets the actual mechanism of neuromuscular impairment. Please refer to our earlier guidance on making a PBAC submission for Vyvgart® (efgartigimod alfa).
The Myasthenia Alliance Australia (MAA) encourages Myasthenia patients and your carers or families/friends to consider making a personal submission by 24 September 2025, highlighting your lived experience and why this treatment could benefit you. Why? Because the patient voice matters.
The MAA will make a submission on your behalf as the organisation representing all Myasthenia patients in Australia. Individual submissions add to this by demonstrating the diversity of our experiences with Myasthenia and the importance of having different treatment options to give us the best care and quality of life.
Not all patients respond in the same way to the same treatment, so options are important. A subcutaneous injection is an injection into the tissue between the skin and the underlying muscle. This type of administration can empower patients, offering the option to self-administer a treatment quickly and not need to go to a hospital, like we do for IV infusions. One-on-one training will be provided for this form of Vyvgart. More information is available on the Vyvgart website.
What can you do next?
Make a submission by Wednesday, 24 September 2025 by completing the online form here.
If you have issues with using the online form, you can send an emaildirectly to commentsPBAC@health.gov.au. If you have difficulties accessing or using technology, please consider asking for help from family, friends or your local librarians.
What should you consider when making a submission?
Your submission to PBAC is guided by 5 questions and can be broken down into two parts:
- In the first part, you tell your story about living with MG and the current treatments you take/receive.
- In the second part, you focus on the advantages and disadvantages of the specific treatment being considered by PBAC.
This means you share your experience of living with MG – this is what you are the expert in! You do not have to have had or tried using the treatments to make a submission and you do not need to discuss the technical or scientific detail.
Talk about your unmet needs with current treatments, the desired benefits of the new treatment, and the outcomes that matter most to you as a patient… if you can imagine any treatment providing you with better management of your symptoms and better quality of life, this is where you can talk about it!
Kind regards,
Susan White (MAA Chairperson)
Natalie Windle (MAA Secretary & MGNSW President)
Carol Buchanan (MAA Board Member & MGAQ President)
**Please note the MAA and state associations do NOT provide medical advice regarding medications or treatments for individuals. Decisions about whether Efgartigimod will be suitable for you as a patient must be discussed with your doctor or health professional. The focus of a consumer submission to PBAC is to describe our patient perspective of living with MG and where/how/why we feel we have unmet needs, uncertainty, and ongoing burden with current treatment options.